trending Market Intelligence /marketintelligence/en/news-insights/trending/1tqtcUxBVB3r1_hRCRh7qA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Qiagen's molecular testing system cleared by US FDA

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity


Qiagen's molecular testing system cleared by US FDA

Qiagen NV said the U.S. Food and Drug Administration granted 510(k) clearance to its molecular diagnostic system QIAstat-Dx.

The Netherlands-based company developed QIAstat-Dx syndromic testing system to detect and identify multiple respiratory viral and bacterial pathogens.

Qiagen launched the QIAstat-Dx syndromic testing system together with its multiplex QIAstat-Dx respiratory panel.